135 related articles for article (PubMed ID: 10370395)
1. Negative U-wave as a predictor of antihypertensive treatment effect on regression of echocardiographic hypertrophy in hypertensive patients.
Kishida H; Saitoh T; Oikawa K; Honma H; Kusama Y
Jpn Heart J; 1999 Jan; 40(1):31-44. PubMed ID: 10370395
[TBL] [Abstract][Full Text] [Related]
2. Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study.
Bang CN; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Roman MJ; Køber L; Wachtell K; Devereux RB
J Hypertens; 2013 Oct; 31(10):2060-8. PubMed ID: 23838656
[TBL] [Abstract][Full Text] [Related]
3. Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.
Bang CN; Gerdts E; Aurigemma GP; Boman K; de Simone G; Dahlöf B; Køber L; Wachtell K; Devereux RB
Circ Cardiovasc Imaging; 2014 May; 7(3):422-9. PubMed ID: 24723582
[TBL] [Abstract][Full Text] [Related]
4. Influence of left ventricular hypertrophy on the diastolic performance in hypertensive patients and in athletes.
Lefkos N; Boudonas G; Vassilicos V; Efthymiadis A
Acta Cardiol; 1993; 48(5):507-14. PubMed ID: 8284991
[TBL] [Abstract][Full Text] [Related]
5. [The effect of hypotensive drugs on left ventricular mass and diastolic function].
Spring A; Haczyński J; Jołda-Mydłowska B; Witkowska M
Pol Arch Med Wewn; 1995 Jul; 94(1):47-58. PubMed ID: 8524699
[TBL] [Abstract][Full Text] [Related]
6. Appropriate or inappropriate left ventricular mass in the presence or absence of prognostically adverse left ventricular hypertrophy.
Mureddu GF; Pasanisi F; Palmieri V; Celentano A; Contaldo F; de Simone G
J Hypertens; 2001 Jun; 19(6):1113-9. PubMed ID: 11403361
[TBL] [Abstract][Full Text] [Related]
7. Left Ventricular Hypertrophy in Hypertensive Athletes can be Reduced by Antihypertensive Medication Despite Continuing Intense Aerobic Exercise.
Ketelhut S; Franz IW; Ketelhut RG
High Blood Press Cardiovasc Prev; 2018 Dec; 25(4):385-390. PubMed ID: 30341642
[TBL] [Abstract][Full Text] [Related]
8. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project.
Schneider MP; Klingbeil AU; Delles C; Ludwig M; Kolloch RE; Krekler M; Stumpe KO; Schmieder RE
Hypertension; 2004 Jul; 44(1):61-6. PubMed ID: 15184349
[TBL] [Abstract][Full Text] [Related]
9. Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study.
Boman K; Gerdts E; Wachtell K; Dahlöf B; Nieminen MS; Olofsson M; Papademetriou V; Devereux RB
Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):242-8. PubMed ID: 19369828
[TBL] [Abstract][Full Text] [Related]
10. Studies on left ventricular hypertrophy regression in arterial hypertension: a clear message for the clinician?
Cuspidi C; Esposito A; Negri F; Sala C; Masaidi M; Giudici V; Zanchetti A; Mancia G
Am J Hypertens; 2008 Apr; 21(4):458-63. PubMed ID: 18369363
[TBL] [Abstract][Full Text] [Related]
11. Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study.
Okin PM; Devereux RB; Liu JE; Oikarinen L; Jern S; Kjeldsen SE; Julius S; Wachtell K; Nieminen MS; Dahlöf B
J Hum Hypertens; 2004 Jun; 18(6):403-9. PubMed ID: 15057252
[TBL] [Abstract][Full Text] [Related]
12. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
Oikarinen L; Nieminen MS; Toivonen L; Viitasalo M; Wachtell K; Papademetriou V; Jern S; Dahlöf B; Devereux RB; Okin PM;
Am Heart J; 2003 May; 145(5):919-25. PubMed ID: 12766755
[TBL] [Abstract][Full Text] [Related]
13. Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study.
Narayan P; Papademetriou V; Wachtell K; Gerdts E; Boman K; Nieminen MS; de Simone G; Dahlöf B; Fyhrquist F; Hoieggen A; Devereux RB
Hypertension; 2006 May; 47(5):868-73. PubMed ID: 16567586
[TBL] [Abstract][Full Text] [Related]
14. Effects of spironolactone-altizide on left ventricular hypertrophy.
Degre S; Detry JM; Unger P; Cosyns J; Brohet C; Kormoss N
Acta Cardiol; 1998; 53(5):261-7. PubMed ID: 9922803
[TBL] [Abstract][Full Text] [Related]
15. Endomyocardial radial strain imaging and left ventricular relaxation abnormalities in patients with hypertrophic cardiomyopathy or hypertensive left ventricular hypertrophy.
Minoshima M; Noda A; Nishizawa T; Hara Y; Sugiura M; Iino S; Nagata K; Koike Y; Murohara T
Circ J; 2009 Dec; 73(12):2294-9. PubMed ID: 19838000
[TBL] [Abstract][Full Text] [Related]
16. Electrocardiographic diagnosis of left ventricular hypertrophy: the effect of left ventricular wall thickness, size, and mass on the specific criteria for left ventricular hypertrophy.
Budhwani N; Patel S; Dwyer EM
Am Heart J; 2005 Apr; 149(4):709-14. PubMed ID: 15990757
[TBL] [Abstract][Full Text] [Related]
17. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
Devereux RB; Palmieri V; Liu JE; Wachtell K; Bella JN; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Dahlöf B
J Hypertens; 2002 Jul; 20(7):1445-50. PubMed ID: 12131543
[TBL] [Abstract][Full Text] [Related]
18. Incremental value of ultrasonic tissue characterization (backscatter) in the evaluation of left ventricular myocardial structure and mechanics in essential arterial hypertension.
Di Bello V; Giorgi D; Talini E; Dell' Omo G; Palagi C; Romano MF; Pedrinelli R; Mariani M
Circulation; 2003 Jan; 107(1):74-80. PubMed ID: 12515746
[TBL] [Abstract][Full Text] [Related]
19. Changes in midwall systolic performance and cardiac hypertrophy reduction in hypertensive patients.
Muiesan ML; Salvetti M; Monteduro C; Rizzoni D; Corbellini C; Castellano M; Porteri E; Agabiti-Rosei E
J Hypertens; 2000 Nov; 18(11):1651-6. PubMed ID: 11081779
[TBL] [Abstract][Full Text] [Related]
20. Left Ventricular Hypertrophy Regression During Antihypertensive Treatment in an Outpatient Clinic (the Campania Salute Network).
Lønnebakken MT; Izzo R; Mancusi C; Gerdts E; Losi MA; Canciello G; Giugliano G; De Luca N; Trimarco B; de Simone G
J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28275070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
